{"id":"W3030566019","doi":"10.1200/jco.2020.38.15_suppl.6002","title":"Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Medicine; Internal medicine; Hazard ratio; Oncology; Placebo; Ovarian cancer; Clinical endpoint; PARP inhibitor; Progression-free survival; BRCA mutation; Chemotherapy; Cancer; Confidence interval; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002522327,0.0009985518,0.001277982,0.0003847377,0.0002523306,0.0009019205,0.0006719499,0.0008456648,0.002904631],"category_scores_gemma":[0.001435209,0.000302351,0.002602811,0.0004733638,0.0004503456,0.0006275983,0.0004641086,0.002304351,0.0004547191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006422756,"about_ca_system_score_gemma":0.0006654084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003507745,"about_ca_topic_score_gemma":0.001018387,"domain_scores_codex":[0.9993227,0.0003536971,0.00004622017,0.0001177011,0.00008559616,0.00007403803],"domain_scores_gemma":[0.9989439,0.0002492419,0.0003444979,0.0000863599,0.00007423406,0.0003018664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.924338,0.003612994,0.01378967,0.0009849425,0.003995138,0.00009607313,0.000107464,0.001688417,0.008343246,0.0001292821,0.002150478,0.04076432],"study_design_scores_gemma":[0.6068068,0.2920919,0.07623515,0.0002092887,0.00902635,0.000649719,0.00008683935,0.002041616,0.005403542,0.0006498247,0.006734279,0.00006472915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872401,0.004505258,0.0005087483,0.0003566416,0.00007272824,0.00118802,0.004058636,0.00005608026,0.002013788],"genre_scores_gemma":[0.9839873,0.001496693,0.001083973,0.0005113753,0.0001094814,0.001475331,0.009684487,0.00002983396,0.001621613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002904631,"threshold_uncertainty_score":0.01333952,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1582817161038081,"score_gpt":0.4573256149871514,"score_spread":0.2990438988833433,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}